Ultrafast-acting insulins are rationally designed as a closer approach to the physiological mealtime insulin action. Faster acting insulin aspart is an ultrafast-acting insulin with an earlier onset of appearance and greater early insulin action than conventional insulin aspart. Fast-acting insulin aspart has demonstrated improvements in PPG increments with reductions in the risk of nocturnal hypoglycemia.